Krystal Biotech, Inc. $KRYS Stake Lessened by S Squared Technology LLC

S Squared Technology LLC reduced its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 11.9% during the 4th quarter, HoldingsChannel reports. The fund owned 96,215 shares of the company’s stock after selling 13,000 shares during the period. Krystal Biotech accounts for 9.2% of S Squared Technology LLC’s portfolio, making the stock its 2nd biggest position. S Squared Technology LLC’s holdings in Krystal Biotech were worth $23,721,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also modified their holdings of the company. Bessemer Group Inc. boosted its stake in shares of Krystal Biotech by 106.9% during the 3rd quarter. Bessemer Group Inc. now owns 149 shares of the company’s stock worth $26,000 after acquiring an additional 77 shares in the last quarter. Sound Income Strategies LLC boosted its stake in shares of Krystal Biotech by 1,270.0% during the 4th quarter. Sound Income Strategies LLC now owns 137 shares of the company’s stock worth $34,000 after acquiring an additional 127 shares in the last quarter. Greenline Wealth Management LLC purchased a new stake in shares of Krystal Biotech during the 4th quarter worth about $34,000. Danske Bank A S purchased a new stake in shares of Krystal Biotech during the 3rd quarter worth about $35,000. Finally, UMB Bank n.a. boosted its stake in shares of Krystal Biotech by 34.6% during the 4th quarter. UMB Bank n.a. now owns 144 shares of the company’s stock worth $36,000 after acquiring an additional 37 shares in the last quarter. 86.29% of the stock is owned by hedge funds and other institutional investors.

Krystal Biotech Price Performance

KRYS opened at $317.97 on Monday. Krystal Biotech, Inc. has a twelve month low of $127.99 and a twelve month high of $331.49. The company has a 50-day moving average price of $288.44 and a 200 day moving average price of $268.27. The company has a market cap of $9.37 billion, a PE ratio of 42.51 and a beta of 0.53.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Monday, May 4th. The company reported $1.83 earnings per share for the quarter, topping the consensus estimate of $1.45 by $0.38. Krystal Biotech had a net margin of 53.92% and a return on equity of 19.25%. The firm had revenue of $116.36 million during the quarter, compared to the consensus estimate of $112.11 million. As a group, sell-side analysts expect that Krystal Biotech, Inc. will post 7.83 earnings per share for the current year.

Insider Activity

In related news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $308.11, for a total transaction of $7,702,750.00. Following the completion of the transaction, the insider owned 1,378,155 shares in the company, valued at $424,623,337.05. This represents a 1.78% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP John Charles Thomas sold 642 shares of the company’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $302.03, for a total transaction of $193,903.26. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.10% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

KRYS has been the topic of several recent analyst reports. HC Wainwright reissued a “buy” rating and set a $310.00 target price on shares of Krystal Biotech in a research note on Monday, June 1st. Wall Street Zen raised shares of Krystal Biotech from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Wolfe Research initiated coverage on shares of Krystal Biotech in a research note on Friday, March 27th. They set a “peer perform” rating on the stock. Jefferies Financial Group increased their target price on shares of Krystal Biotech from $310.00 to $371.00 and gave the stock a “buy” rating in a research note on Tuesday, February 17th. Finally, Evercore restated an “outperform” rating and set a $300.00 price target on shares of Krystal Biotech in a research report on Tuesday, May 5th. Ten equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $324.11.

Krystal Biotech Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.